ABSTRACT

Several neurological conditions share a characteristic feature: an increase in intracellular calcium levels ([Ca^{2+}]_i). It has been demonstrated that calcium influx induces changes ranging from an increase in the expression levels of several genes to the activation of proteases such as calpains. Calpains are a family of Ca^{2+}-dependent non-lysosomal cysteine proteases, whose substrates include several proteins that play critical roles in several cellular functions including synaptic plasticity and neuronal apoptosis.

TrkB is a type of tyrosine related kinase receptor that can promote neuronal survival and differentiation upon ligand binding. It has been recently shown that in several neurological diseases, the level of full-length TrkB protein decreases before the onset of neuronal death due to one of two different processes: a) a reverse regulation of TrkB isoforms mRNA, or b) calpain-mediated processing of TrkB full-length, which yields a truncated form of TrkB (Tc-TrkB). Because the most notorious feature of calpain proteolytic activity is that the products of calpain-mediated cleavage may have biological activity, here we review the hypotheses by which calpain-generated isoform Tc-TrkB may perform biological functions.

TrkB and the calpain dependent-Tc TrkB receptor isoforms: possible neurological therapeutic targets

Victor Danelon1, Andrea B. Cragnolini1, Daniel Mascó1*

1Laboratorio de Neurobiología, Instituto de Investigaciones Biológicas y Tecnológicas, IIByT-CONICET-FCEFyN, Universidad Nacional de Córdoba, Av. Vélez Sarsfield 1611, Córdoba, Argentina.

© 2016 Mascó DH. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License

Keywords: TrkB TrkB-Tk Tc-TrkB Calpain Neurological conditions intracellular calcium levels

Abbreviations

BDNF: Brain Derived Neurotrophic Factor; Gdk5 (Cyclin-Dependent Kinase 5); CNS: Central Nervous System; Erk/MAPK: extracellular related kinase ICD: intracellular fragment; NCX: Na^{+}–Ca^{2+} exchanger; NMDAr: N-Methyl-D-Aspartate receptor; NT: neurotrophins; NT4: Neurotrophin 4; p75 NTR: 75 neurotrophin receptor; PI3K: Phosphoinositide 3-kinase; PKC: protein kinase C; PKM: protein kinase M; PLC: phospholipase c; proBDNF: BDNF immature isoform; PSD: Postsynaptic Density Protein; SE: status epilepticus; Tc-TrkB: calpain-truncated TrkB receptor; TrkB-Tk: truncated TrkB receptor; TrkB: full-length Tropomyosin related Kinase B Receptor; TrkB-ICD: intracellular fragment of TrkB;

Introduction

Neurotrophins (NT) are a set of proteins that act through high affinity receptors found on the cell surface. Over the past two decades, there has been a major increase in NT research studies, especially in the Central Nervous System (CNS). NT play a critical role not only in the development and maintenance of the nervous system, but also in neuropathological disorders. It has been suggested that endogenous changes in NT expression can contribute to the development of neurological conditions. To study NT function
is challenging due to the different biological outcomes they elicit, which range from trophic, survival, or neuritogenic differentiation to, putatively, neuronal death. The NT, more precisely BDNF (Brain Derived Neurotrophic Factor), triggers signal transduction by binding to TrkB (Tropomyosin receptor kinase B) and p75NTR (p 75 neurotrophins receptor) receptors.

Several TrkB receptor isoforms have been described, and are abundantly expressed in the brain: a full-length TrkB (TrkB), and the truncated isoforms TrkB-Tk. TrkB activation trigger different intracellular signaling cascades, including mitogen-activated protein kinase/extracellular signal regulated protein kinase (MAPK/ERK), the phospholipase C-γ (PLCγ), and the phosphoinositide-3 kinase (PI3K)/protein kinase B (AKT) pathways, which in turn induce cellular processes such as differentiation, proliferation and survival in different cell types. Moreover, these physiological processes are regulated by different mechanisms, such as spatial and temporal changes in the level of TrkB ligands, the ratio between TrkB and TrkB-Tk, intracellular signaling pathways, and gene expression. Despite the fact that the biological role of TrkB-Tk receptor isoforms is not yet fully known, it has been recently associated with several functions in neurons and glial cells, such as the regulation of BDNF levels at the extracellular site, the activation of intracellular signaling pathways, morphological changes in neurons and glial cells, and dominant-negative inhibition of TrkB signaling. Since the function and signaling of TrkB-Tk receptor has been described in detail in excellent reviews, they are beyond the scope of this revision.

Together TrkB and the described isoforms have recently been associated with several neurological conditions that affect the CNS, such as ischemia, Alzheimer’s disease (AD), and status epilepticus (SE), where excitotoxic insults disrupt the balance among TrkB/TrkB-Tk/p75NTR ratio. The imbalance observed results in a truncated protein, Tc-TrkB, which lacks the remaining intracellular fragment (TrkB-ICD) contains the Shc-binding site, whereas the receptor contains the Shc-binding site, whereas the calpain generates two TrkB-derived proteins. On one hand, this imbalance produces a decrease at the level of both TrkB transcripts and protein. On the other hand, evidence indicates that TrkB-Tk and p75NTR receptor levels increase due to upregulated at the transcriptional and translational levels, since inhibitors of both processes prevent the excitotoxic-induced upregulation observed. Thus, it can be inferred that trkb mRNA splicing mechanisms may change under excitotoxic conditions. Even though there are increasing evidences supporting these findings, the biological consequences of the TrkB/TrkB-Tk imbalance is still a matter of debate.

Also it has been demonstrated that BDNF/proBDNF (BDNF immature isoform) have key roles in determine neuronal death once the pathology has occurred. In vivo results from our lab show when intra-hippocampal infusion of function-blocking antibodies against BDNF avoided the down-regulation of TrkB and prevent neuronal death following the SE insult. In line with this, the infusion of BDNF protein after SE exacerbated neuronal degeneration and surprisingly, inhibiting BDNF protein synthesis, due to the infusion of antisense oligonucleotides, induced a rapid decrease of BDNF protein levels, and SE-induced neuronal damage was prevented. These results show that there is a complex interplay between the NT and their receptors before the onset of neuronal death.

Calpain proteolysis mediates the TrkB receptor degradation following an excitotoxic insult

Neuronal depolarization induces an increase in intracellular calcium levels ([Ca²⁺]), which exerts a variety of functions, ranging from increased expression of several genes to the activation of proteases such as calpain. Calpains constitute a family of Ca²⁺-dependent non-lysosomal cysteine proteases that play key roles in various cellular functions, including synaptic plasticity and neuronal apoptosis. To achieve its functions, calpain acts on different substrates, including cytoskeletal proteins (e.g. α-spectrin, neurofilaments), membrane receptors (e.g. NMDA receptor), and other proteases. When active, calpain modifies the structure and activity of their targets by limited proteolysis. Calpains have two modes of action depending on the [Ca²⁺] found in the cytoplasm: in a physiological way and in pathological conditions, where there is calcium overload mainly by over-activation of the NMDA receptor (NMDAr), resulting in calpain overactivation. It has been recently observed that, in ischemia, AD, and experimental SE models, a drop in TrkB level is not only due to a decrease at the transcriptional level. A TrkB-calpain-dependent-processing is another mechanism that cooperates with the imbalance observed. This proteolytic cleavage results in a truncated protein, Trc-TrkB, which lacks the tyrosine-kinase domain, and it is comparable to the synthesized TrkB-Tk isoform (first demonstrated by Vidaurre et al.44). Jeronimo-Santos et al.24 has confirmed these results, and established that the TrkB site for calpain-cleavage is located between the Shc-binding site (Tyr515) and the Trk kinase domain. Consequently, the Trc-TrkB receptor contains the Shc-binding site, whereas the remaining intracellular fragment (TrkB-ICD) contains the complete tyrosine kinase domain of TrkB receptor. These data indicate that the proteolytic processing triggered by calpain generates two TrkB-derived proteins.

Tc-TrkB increases in the dendritic and axonal domains before the onset of neuronal death

Degeneration of neuritic processes in neurons is an early event in a wide range of neurodegenerative diseases
as well as in other neurological conditions. We found that the neurotrophin receptor TrkB is proteolitically processed by calpain in the dendritic and axonal domains of neurons committed to die, and this constitutes an early step in the neuronal degenerative process. While the TrkB level decreases, the Tc-TrkB concurrently increases, leading to a TrkB/Tc-TrkB imbalance, which we believe is linked to neurodegeneration. When a specific calpain activity blocker agent was used, the TrkB/Tc-TrkB imbalance was prevented, the neuronal processes were protected from degeneration and an enhanced neuronal survival was observed. Additionally, ANA-12, a specific TrkB antagonist, blocked SE-induced neuronal death. By the time that ANA-12 was added to the neurons in culture, a significant decrease in the level of TrkB had already occurred. Thus, we believe that the observed effect of the ANA-12 antagonist did not result from TrkB inhibition, but mostly from an effect on Tc-TrkB. Others have shown an increase in the synthesis of TrkB-Tk receptor following excitotoxic stimulation, which takes place prior to the onset of neuronal death. However, the possibility that neuronal death is prevented by ANA-12 through inhibition of signaling pathways downstream TrkB-Tk can be discarded, since blocking TrkB-Tk protein synthesis did not affect neuronal death. It will be important to further investigate the biological role of Tc-TrkB in this process.

**Tc-TrkB may acquire a biological function following calpain-dependent TrkB processing**

Several studies show that some proteolytic products of calpain-mediated cleavage carry biological activity. A well-known example of a calpain substrate proteolytic product with biological activity is the p35 protein, a neuron-specific activator of cyclin-dependent kinase 5 (CDK5). When calpain is activated, p35 cleavage results in p25, which steadily activates CDK5, and p10 proteins, also biologically active. This cyclin-dependent kinase has been implicated in several biological functions, including modulation of synaptic plasticity and hyperphosphorylation of Tau protein, an AD hallmark. Similarly to the dual functions of CDK5, the metabotropic glutamate receptor mGluR1α has also the potential to be neuroprotective as well as to contribute to neurotoxicity. In an excitotoxic model, calpain mediates the proteolytic cleavage of the C-terminal tail of mGluR1α which impair its capability to induce neuroprotective effects via Akt activation. The cleavage of mGluR1α helps to maintain a positive feedback regulation in excitotoxicity (involving calpain and mGluR1α), which results in a pathological intracellular calcium increase. In line with the latter, another calpain target includes the NCX3 subtype of the Na⁺-Ca²⁺ exchanger (NCX) whose proteolytic inactivation helps to maintain high cytoplasmic calcium levels.

Several studies have shown that calpain-processed proteins have effects at the synaptic level by modulating burst firing and by modifying the localization of receptors in normal and pathological conditions. Calpain cleaves protein kinase C (PKC) which releases the active protein kinase M fragment (PKM) which can modulate the development and maintenance of burst firing, a process that enhances neurotransmitter release to the synaptic cleft. The postsynaptic density protein 95 (PSD-95), a scaffold protein that clusters several receptors together, is also a calpain target. When the PSD-95 is cleaved, the anchoring of NMDAR is modified. Furthermore, the neurotrophin receptor p75 undergoes receptor cleavage releasing ICD fragments with cellular functions. Moreover, the neurotrophin receptor p75 undergoes rapid α- and γ-secretase-dependent cleavage, following neurotrophin-mediated Trk activation. Therefore, p75 receptor cleavage releases ICD, which facilitates NT-Trk-dependent Akt activation.

Based on all the information supporting a functional role of calpain-cleaved products, it would not be surprising to find that the TrkB-calpain-cleaved products can perform a biological function.

**Therapeutic targeting of the TrkB receptor**

In this article, after reviewing the latest knowledge of TrkB processing by calpain, we discuss the rationale underlying the selective targeting of calpain to prevent the TrkB-mediated neuronal death. A good strategy has to be proposed in order to prevent the axonal and dendritic domain degeneration once the pathology has occurred. Among them to be considered is the intraperitoneal administration (i.p.) of a calpain activity blocker, as was already been demonstrated by Araujo et al. Using kainic acid (KA) as an *in vivo* model of SE, Araujo et al. demonstrated that i.p. infusion of MDL 28170, a calpain activity blocker that pass through the blood-brain barrier, avoided the extent of the lesion in the CA1 area.
in the hippocampus of KA-injected rats. Whether the i.p. administration of the calpain activity blocker prevents the increase in the Tc-TrkB in the axonal and dendritic domain and thus, explain the decrease in the neurodegeneration, is a good hypothesis to be tested in order to develop new pharmacological treatment once the pathology has occurred.

Another plausible therapeutic strategy to prevent neurodegeneration would be the inhibition of the BDNF-protein synthesis. We already showed that this approach markedly decrease neuronal death after SE in vivo. In line with this, others have shown that inhibiting the BDNF-TrkB complex it is associated with a decreased in the epileptogenesis in SE models. New strategies to avoid neurodegeneration can be focus on TrkB processing with the aim of developing promising strategies to treat SE patients.

**Concluding remarks**

Recently published results indicate that physiological or pathological increase in \([\text{Ca}^{2+}]_i\) induces an increase in...
calpain activation, which, in turn, leads to the proteolytic cleavage of several substrates. The excitotoxic insult selectively upregulates TrkB-Tk protein level. Also, it simultaneously decreases TrkB level via transcriptional deregulation and by increasing TrkB calpain-proteolytic cleavage. This process results in two new isoforms: Tc-TrkB and TrkB-ICD. Further experiments are needed to elucidate whether both calpain-dependent-TrkB-cleaved products may acquire new biological functions.

Acknowledgement

Authors wish to acknowledge the assistance of the CONICET and UNC, both of which support facilities used in this investigation. This work was funded by CONICET, SeCyT-UNC and FONCyT (PICT #21000). D.H.M and A.B.C are career members of CONICET, V.D. was a recipient of doctoral fellowship from CONICET.

References